Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation
NCT ID: NCT01340105
Last Updated: 2022-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
93 participants
INTERVENTIONAL
2011-04-30
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that microwave ablation can achieve a better complete ablation rate as compared to radiofrerquency ablation.
A randomized comparative study is performed by randomly assigned participants to microwave ablation arm or radiofrequency ablation arm. The efficacy of treatment outcome is assessed by the complete tumor ablation rate at 1 month, recurrence rate and survival time of participants. Safety of the procedures is also compared between the 2 treatment arms.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Microwave and Radiofrequency Ablation for Liver
NCT02539212
Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
NCT00132041
Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma
NCT00554905
Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
NCT00814242
Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic Vessels
NCT03063840
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Microwave
Hepatocellular carcinoma treated with microwave ablation
Microwave ablation
Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Radiofrequency
Hepatocellular carcinoma treated with radiofrequency ablation
Radiofrequency ablation
Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Microwave ablation
Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Radiofrequency ablation
Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Unresectable hepatocellular carcinoma (HCC) and tumor amendable for local ablation
* Resectable HCC but patient opts for local ablation
* Maximum diameter of tumor ≤6cm
* Maximum number of tumor nodules ≤3
* Absence of radiology evidence of major vascular or bile duct invasion
* Child's A or B liver function
* Karnofsky performance status ≥70%
Exclusion Criteria
* Pregnant female patients
* Tumors unfavourable for local ablation (e.g. tumor close to porta hepatis)
* HCC with history of rupture
* Concomitant hepatectomy
* Patients with chronic renal failure
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cheung Yue Sun
Associate Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kit-fai Lee, MBBS
Role: PRINCIPAL_INVESTIGATOR
Department of Surgery, The Chinese University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prince of Wales Hospital
Hong Kong, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT11005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.